Amid Brexit Chaos, UK Defers Life Sciences Spending Commitments
Sector wants R&D tax credits updated, investment in Biomedical Catalyst, and is dismayed by spending delay.
You may also be interested in...
Timing means full EU approval could coincide with US FDA authorization later this year.
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
Analysts are confident that Pfizer/BioNTech’s mRNA vaccine will prove its safety and efficacy – but waiting a little longer for more robust data could be for the best.